Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alterations by thalidomide treatment

Wenlin Du, Yutaka Hattori, Akinori Hashiguchi, Kensuke Kondoh, Nobumichi Hozumi, Yasuo Ikeda, Michiie Sakamoto, Jun Ichi Hata, Taketo Yamada

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Angiogenesis in solid tumors is important to tumor growth, invasion and metastasis. Recently, it has been suggested that angiogenesis plays a certain role in the development of hematopoietic malignancies, including leukemia and multiple myeloma. We evaluated tumor angiogenesis in the bone marrow (BM) of multiple myeloma (MM) patients by calculating microvessel density (MVD) in needle-biopsy specimens obtained from 51 cases of untreated MM or monoclonal gammopathy of undetermined significance (MGUS). The MVD in the BM of donors for transplantation and patients with non-hematological diseases was calculated as a control. There was an obvious increase in MVD in the BM of MM patients, and the MVD correlated with the grade of myeloma cell invasion of the BM in the untreated MM cases. It was recently reported that thalidomide might be effective for the treatment of MM. We assessed the effect of thalidomide on angiogenesis in BM treatment of 11 patients with refractory MM. The concentration of M-protein in the serum or urine of seven of the 11 patients was reduced by at least 30% after thalidomide treatment, and MVD in the BM decreased in three of these seven cases in response to thalidomide. Increased plasma concentrations of basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF) were observed in all 11 cases before thalidomide administration and both levels were reduced after treatment with thalidomide. Augmented angiogenesis in the bone marrow of MM patients was confirmed in the present study. It seems that thalidomide is effective in the treatment of MM through the impairment of angiogenesis by decreasing FGF-2 and VEGF production. This is the first report on pathological evidence in the bone marrow of MM before and after thalidomide treatment, in Japan.

Original languageEnglish
Pages (from-to)285-294
Number of pages10
JournalPathology International
Volume54
Issue number5
DOIs
Publication statusPublished - 2004 May

Fingerprint

Thalidomide
Multiple Myeloma
Bone Marrow
Microvessels
Fibroblast Growth Factor 2
Neoplasms
Therapeutics
Vascular Endothelial Growth Factor A
Monoclonal Gammopathy of Undetermined Significance
Needle Biopsy
Hematologic Neoplasms
Bone Marrow Transplantation
Bone Marrow Cells
Blood Proteins
Japan
Leukemia
Tissue Donors
Urine
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • CD34
  • Fibroblast growth factor
  • Multiple myeloma
  • Thalidomide
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alterations by thalidomide treatment. / Du, Wenlin; Hattori, Yutaka; Hashiguchi, Akinori; Kondoh, Kensuke; Hozumi, Nobumichi; Ikeda, Yasuo; Sakamoto, Michiie; Hata, Jun Ichi; Yamada, Taketo.

In: Pathology International, Vol. 54, No. 5, 05.2004, p. 285-294.

Research output: Contribution to journalArticle

Du, Wenlin ; Hattori, Yutaka ; Hashiguchi, Akinori ; Kondoh, Kensuke ; Hozumi, Nobumichi ; Ikeda, Yasuo ; Sakamoto, Michiie ; Hata, Jun Ichi ; Yamada, Taketo. / Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alterations by thalidomide treatment. In: Pathology International. 2004 ; Vol. 54, No. 5. pp. 285-294.
@article{1ffd009f56fd4884912b5b51817c756f,
title = "Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alterations by thalidomide treatment",
abstract = "Angiogenesis in solid tumors is important to tumor growth, invasion and metastasis. Recently, it has been suggested that angiogenesis plays a certain role in the development of hematopoietic malignancies, including leukemia and multiple myeloma. We evaluated tumor angiogenesis in the bone marrow (BM) of multiple myeloma (MM) patients by calculating microvessel density (MVD) in needle-biopsy specimens obtained from 51 cases of untreated MM or monoclonal gammopathy of undetermined significance (MGUS). The MVD in the BM of donors for transplantation and patients with non-hematological diseases was calculated as a control. There was an obvious increase in MVD in the BM of MM patients, and the MVD correlated with the grade of myeloma cell invasion of the BM in the untreated MM cases. It was recently reported that thalidomide might be effective for the treatment of MM. We assessed the effect of thalidomide on angiogenesis in BM treatment of 11 patients with refractory MM. The concentration of M-protein in the serum or urine of seven of the 11 patients was reduced by at least 30{\%} after thalidomide treatment, and MVD in the BM decreased in three of these seven cases in response to thalidomide. Increased plasma concentrations of basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF) were observed in all 11 cases before thalidomide administration and both levels were reduced after treatment with thalidomide. Augmented angiogenesis in the bone marrow of MM patients was confirmed in the present study. It seems that thalidomide is effective in the treatment of MM through the impairment of angiogenesis by decreasing FGF-2 and VEGF production. This is the first report on pathological evidence in the bone marrow of MM before and after thalidomide treatment, in Japan.",
keywords = "Angiogenesis, CD34, Fibroblast growth factor, Multiple myeloma, Thalidomide, Vascular endothelial growth factor",
author = "Wenlin Du and Yutaka Hattori and Akinori Hashiguchi and Kensuke Kondoh and Nobumichi Hozumi and Yasuo Ikeda and Michiie Sakamoto and Hata, {Jun Ichi} and Taketo Yamada",
year = "2004",
month = "5",
doi = "10.1111/j.1440-1827.2004.01622.x",
language = "English",
volume = "54",
pages = "285--294",
journal = "Pathology International",
issn = "1320-5463",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alterations by thalidomide treatment

AU - Du, Wenlin

AU - Hattori, Yutaka

AU - Hashiguchi, Akinori

AU - Kondoh, Kensuke

AU - Hozumi, Nobumichi

AU - Ikeda, Yasuo

AU - Sakamoto, Michiie

AU - Hata, Jun Ichi

AU - Yamada, Taketo

PY - 2004/5

Y1 - 2004/5

N2 - Angiogenesis in solid tumors is important to tumor growth, invasion and metastasis. Recently, it has been suggested that angiogenesis plays a certain role in the development of hematopoietic malignancies, including leukemia and multiple myeloma. We evaluated tumor angiogenesis in the bone marrow (BM) of multiple myeloma (MM) patients by calculating microvessel density (MVD) in needle-biopsy specimens obtained from 51 cases of untreated MM or monoclonal gammopathy of undetermined significance (MGUS). The MVD in the BM of donors for transplantation and patients with non-hematological diseases was calculated as a control. There was an obvious increase in MVD in the BM of MM patients, and the MVD correlated with the grade of myeloma cell invasion of the BM in the untreated MM cases. It was recently reported that thalidomide might be effective for the treatment of MM. We assessed the effect of thalidomide on angiogenesis in BM treatment of 11 patients with refractory MM. The concentration of M-protein in the serum or urine of seven of the 11 patients was reduced by at least 30% after thalidomide treatment, and MVD in the BM decreased in three of these seven cases in response to thalidomide. Increased plasma concentrations of basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF) were observed in all 11 cases before thalidomide administration and both levels were reduced after treatment with thalidomide. Augmented angiogenesis in the bone marrow of MM patients was confirmed in the present study. It seems that thalidomide is effective in the treatment of MM through the impairment of angiogenesis by decreasing FGF-2 and VEGF production. This is the first report on pathological evidence in the bone marrow of MM before and after thalidomide treatment, in Japan.

AB - Angiogenesis in solid tumors is important to tumor growth, invasion and metastasis. Recently, it has been suggested that angiogenesis plays a certain role in the development of hematopoietic malignancies, including leukemia and multiple myeloma. We evaluated tumor angiogenesis in the bone marrow (BM) of multiple myeloma (MM) patients by calculating microvessel density (MVD) in needle-biopsy specimens obtained from 51 cases of untreated MM or monoclonal gammopathy of undetermined significance (MGUS). The MVD in the BM of donors for transplantation and patients with non-hematological diseases was calculated as a control. There was an obvious increase in MVD in the BM of MM patients, and the MVD correlated with the grade of myeloma cell invasion of the BM in the untreated MM cases. It was recently reported that thalidomide might be effective for the treatment of MM. We assessed the effect of thalidomide on angiogenesis in BM treatment of 11 patients with refractory MM. The concentration of M-protein in the serum or urine of seven of the 11 patients was reduced by at least 30% after thalidomide treatment, and MVD in the BM decreased in three of these seven cases in response to thalidomide. Increased plasma concentrations of basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF) were observed in all 11 cases before thalidomide administration and both levels were reduced after treatment with thalidomide. Augmented angiogenesis in the bone marrow of MM patients was confirmed in the present study. It seems that thalidomide is effective in the treatment of MM through the impairment of angiogenesis by decreasing FGF-2 and VEGF production. This is the first report on pathological evidence in the bone marrow of MM before and after thalidomide treatment, in Japan.

KW - Angiogenesis

KW - CD34

KW - Fibroblast growth factor

KW - Multiple myeloma

KW - Thalidomide

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=2642520461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642520461&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1827.2004.01622.x

DO - 10.1111/j.1440-1827.2004.01622.x

M3 - Article

C2 - 15086832

AN - SCOPUS:2642520461

VL - 54

SP - 285

EP - 294

JO - Pathology International

JF - Pathology International

SN - 1320-5463

IS - 5

ER -